ReviewNuclear medicine and biology2007
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.
Review in Nuclear medicine and biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 233 citations in OpenAlex.
- Diverse DTPA-chelated lanthanides with relevance for nuclear medicine bound to an engineered lipocalin reveal conserved ligand geometry.Acta crystallographica. Section F, Structural biology communications · 2026Article
- Radioligand-Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis.Molecular diagnosis & therapy · 2026Review
- Contemporary opportunities and potential of Auger electron-emitting theranostics.Theranostics · 2026Review
- Microendoscopy for periodic intravital end-to-end tumor imaging of cancer cells.Cell reports methods · 2025Article
- Dual Potential of Cetuximab Conjugated Hydroxyapatite Zirconium Nanoparticle as Nanocarrier for Radioenhancer in X-Ray Dynamic Therapy andNanotheranostics · 2025Article
- Stimuli-responsive linkers and their application in molecular imaging.Exploration (Beijing, China) · 2024Review
- Optimal Indications of Radioimmunotherapy in Nuclear Medicine: A Mini-Review.Current radiopharmaceuticals · 2024Review
- Review
- Implications of hydrogen sulfide in colorectal cancer: Mechanistic insights and diagnostic and therapeutic strategies.Redox biology · 2023Review
- The application of radionuclide therapy for breast cancer.Frontiers in nuclear medicine · 2023Review
- Bifunctional chelators for radiorhenium: past, present and future outlook.RSC medicinal chemistry · 2022Review
- Review
- Immuno-PET: Design options and clinical proof-of-concept.Frontiers in medicine · 2022Review
- Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios ofMolecules (Basel, Switzerland) · 2021Article
- Lipophilicity and Click Reactivity Determine the Performance of Bioorthogonal Tetrazine Tools in PretargetedACS pharmacology & translational science · 2021Article
- Agent Optimization: Absorption, Distribution, Metabolism, Excretion, Dose, and Decay.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target.Therapeutic advances in medical oncology · 2021Article
- Perspectives on metals-based radioimmunotherapy (RIT): moving forward.Theranostics · 2021Review
- Imaging Hydrogen Sulfide in Hypoxic Tissue with [Molecules (Basel, Switzerland) · 2020Article
- Anti-PSMAJournal of experimental & clinical cancer research : CR · 2019Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Only a handful of radiolabeled antibodies (Abs) have gained US Food and Drug Administration (FDA) approval for use in clinical oncology, including four immunodiagnostic agents and two targeted radioimmunotherapeutic agents. Despite the advent of nonimmunogenic Abs and the availability of a diverse library of radionuclides, progress beyond early Phase II radioimmunotherapy (RIT) studies in solid tumors has been marginal. Furthermore, [18F]fluorodeoxyglucose continues to dominate the molecular imaging domain, underscored by a decade-long absence of any newly approved Ab-based imaging agent (none since 1996). Why has the development of clinically successful Abs for RIT been limited to lymphoma? What obstacles must be overcome to allow the FDA approval of immuno-positron emission tomography (immuno-PET) imaging agents? How can we address the unique challenges that have thus far prevented the introduction of Ab-based imaging agents and therapeutics for solid tumors? Many poor decisions have been made regarding radiolabeled Abs, but useful insight can be gained from these mistakes. The following review addresses the physical, chemical, biological, clinical, regulatory and financial limitations that impede the progress of this increasingly important class of drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.